GCP
SPRO icon

GSA Capital Partners’s Spero Therapeutics SPRO Stock Holding History

GSA Capital Partners’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$632K Buy
285,906
+7,602
+3% +$19.9K 0.04% 843
2026
Q1 		$651K Buy
278,304
+99,374
+56% +$236K 0.04% 754
2025
Q4 		$417K Buy
178,930
+72,036
+67% +$167K 0.04% 942
2025
Q3 		$201K Buy
+106,894
New +$235K 0.02% 1430
2024
Q2 		– Sell
-28,319
Closed -$49K – 1999
2024
Q1 		$49K Buy
+28,319
New +$44.4K ﹤0.01% 1535
2022
Q3 		– Sell
-10,450
Closed -$8K – 1836
2022
Q2 		$8K Sell
10,450
-15,466
-60% -$45K ﹤0.01% 1333
2022
Q1 		$225K Buy
+25,916
New +$266K 0.03% 1104

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GSA Capital Partners's SPRO Position: Q2 2026 in Review

GSA Capital Partners increased its Spero Therapeutics (SPRO) stake by 2.7% in Q2 2026, buying an estimated $19.9K and bringing the position to 285,906 shares worth $632K. The position accounts for 0.04% of the portfolio, ranked #843.

GSA Capital Partners first reported a position in SPRO in Q1 2022 and has held it in 7 quarters since. The position peaked at $651K in Q1 2026. 34 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • GSA Capital Partners held 285,906 shares of Spero Therapeutics worth $632K as of Q2 2026.
  • GSA Capital Partners bought 7,602 Spero Therapeutics shares in Q2 2026, an estimated $19.9K.
  • Spero Therapeutics made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #843 holding.
  • GSA Capital Partners first reported a position in Spero Therapeutics in Q1 2022 and has held it in 7 quarters since.
  • GSA Capital Partners's Spero Therapeutics position peaked at $651K in Q1 2026.
  • 34 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.